Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care

Wathen, C. Nadine; Feig, Denice S.; Feightner, John W.; Abramson, Beth L.; Cheung, Angela M.
May 2004
CMAJ: Canadian Medical Association Journal;5/11/2004, Vol. 170 Issue 10, p1535
Academic Journal
Provides information on hormone replacement therapy (HRT) for primary prevention of chronic diseases in the Canada. Recommendations of the Canadian Task Force on Preventive Health Care for HRT therapy in the country; Risk of breast cancer among women using HRT for the treatment of menopausal symptoms; Evidence on the positive and negative effects of HRT based on clinical trials conducted in the country.


Related Articles

  • Breast Ducts: A New Site for Cancer Treatment?  // Ascribe Newswire: Medicine;1/25/2006, p1 

    This article reports that Johns Hopkins Kimmel Cancer Center researchers are studying whether delivering chemotherapy drugs directly to breast plumbing might make treatment of early breast cancer easier on the patient and at least as good as surgery or radiation. A report on successful tests of...

  • Dietary Fat and Breast Cancer: Contributions From a Survival Trial. Thi�E9;baut, Anne C. M.; Schatzkin, Arthur; Ballard-Barbash, Rachel; Kipnis, Victor // JNCI: Journal of the National Cancer Institute;12/20/2006, Vol. 98 Issue 24, p1753 

    The authors reflects on the relation between breast cancer and dietary fat taken from contributions from a survival trial. The authors reflect that medical hypotheses correlating dietary fat to incidents of breast cancer show inconsistent results. They focus on the result on a low-fat...

  • The National Randomised Trial of Hormone Replacement Therapy in Women with a History of Early Stage Breast Cancer. Marsden, Jo // Journal of the British Menopause Society;2001, Vol. 7 Issue 2, p52 

    The article reports on the establishment of a national randomized trial of hormone replace therapy in women with a history of early stage breast cancer in Great Britain. 3,000 women will be recruited in the trial. The trial is funded by the Cancer Research Campaign and NHS Research and...

  • Radical mastectomy is no better than less radical approaches. Fisher, B; Jeong, JH; Anderson, S // Contemporary OB/GYN;Feb2003, Vol. 48 Issue 2, p20 

    The article discusses findings of a follow-up of a randomized trial comparing radical mastectomy, total mastectomy and total mastectomy followed by irradiation. The study suggest that radical mastectomy has no significant survival advantage to women with breast cancer, when compared to total...

  • Is less radiation after lumpectomy feasible?  // Contemporary OB/GYN;Oct2008, Vol. 53 Issue 10, p24 

    The article reports on the result of two large clinical trials on the use radiation after lumpectomy in breast cancer, which are published in the 2008 issue of the "Journal of the National Cancer Institute." In the Standardization of Breast Radiotherapy Trial, hypofractionation can be utilized...

  • The ROI of PEM. Schilling, Kathy // Imaging Economics;Oct2011, Vol. 24 Issue 9, p24 

    The article discusses the aspects of positron emission mammography (PEM) clinical trial that offers state of the art breast cancer imaging technology. It states that PEM offers a 3D tomographic view of breast, which enables the doctor to easily determine the exact location of the lesion....

  • Which benefit from adding gemcitabine to vinorelbine in elderly (≥70 years) women with metastatic breast cancer? Early interruption of a phase II study. U Basso; L Fratino; A Brunello; F Lumachi; GL De Salvo; S Lonardi; C Ghiotto; H Koussis; LM Pasetto; S Monfardini // Annals of Oncology;Jan2007, Vol. 18 Issue 1, p58 

    Background: Since vinorelbine and gemcitabine are both active in breast cancer with moderate toxicity, in 2002 we started a phase II trial with a combination regimen in elderly patients.Patients and methods: To evaluate complete plus partial response rates and toxicity of first-line vinorelbine...

  • Modeling the effect of age in T1-2 breast cancer using the SEER database. Tai, Patricia; Cserni, Gábor; van de Steene, Jan; Vlastos, Georges; Voordeckers, Mia; Royce, Melanie; Sang-Joon Lee; Vinh-Hung, Vincent; Storme, Guy // BMC Cancer;2005, Vol. 5, p130 

    Background: Modeling the relationship between age and mortality for breast cancer patients may have important prognostic and therapeutic implications. Methods: Data from 9 registries of the Surveillance, Epidemiology, and End Results Program (SEER) of the United States were used. This study...

  • Can Tamoxifen Reduce the Risk of Breast Cancer? Walling, Anne D. // American Family Physician;2/1/2003, Vol. 67 Issue 3, p618 

    Discusses the study 'First Results From the International Breast Cancer Intervention Study (IBIS-I): A Randomized Prevention Trial,' from the September 14, 2002 issue of 'The Lancet.'

  • AN INNOVATIVE DESIGN FOR IMMEDIATE SUBJECT ACCRUAL FOR RESEARCH. Lemler, Suzanne; Thompson, Barbara; Rush-Taylor, Anita; Murphy, Vivian; Christmon, Darlene; Coleman, Nicki // Oncology Nursing Forum;Mar2006, Vol. 33 Issue 2, p458 

    The ability to recruit and conduct a study on a large number of subjects in a clinical trial in an efficient amount of time has been an ongoing challenge. In order to evaluate the role of polymorphic differences in genes important in the angiogenesis pathway in breast cancer, 1000 women (500...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics